IRAK1/4 and BET bromodomain inhibitions converge on NF-κB blockade and display synergistic antitumor activity in ABC-DLBCL with MYD88L265P mutation
收藏NIAID Data Ecosystem2026-03-12 收录
下载链接：
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE159915
下载链接
链接失效反馈官方服务：
资源简介：
Diffuse large B cell lymphoma cell lines of the activated B cell subtype (ABC-DLBCL) were treated for 6h with IRAK1/4 inhibitor (50µM) followed or not by a 18h exposure to 500 nM CPI203 We used microarrays to uncover the mechanisms underlying IRAKi+BETi activity in ABC-DLBCL Global RNA expression was done in three ABC-DLBCL cell lines treated in vitro with IRAKi (6h) +/- BETi (18h)
创建时间：
2020-10-26
